Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Feb 14;229(2):367-375.
doi: 10.1093/infdis/jiad307.

A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years

Shon Remich  1 , Nicholas Kitchin  2 , James Peterson  3 , Ping Li  1 , Michael W Pride  4 , Linda Brock  4 , Annaliesa S Anderson  4 , William C Gruber  4 , Kathrin U Jansen  4 , Stephen P Lockhart  2 , Chris Webber  2
Affiliations
Clinical Trial

A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years

Shon Remich et al. J Infect Dis. .

Abstract

Background: This phase 2 extension explored the long-term antibody persistence of an investigational Clostridioides difficile vaccine and the safety, tolerability, and immunogenicity of dose 4 approximately 12 months post-dose 3.

Methods: One year post-dose 3, healthy US 65- to 85-year-olds (N = 300) were randomized to dose 4 of vaccine at previously received antigen levels (100 or 200 μg) or placebo. Assessments included safety and percentages of participants achieving neutralizing antibody titers above prespecified thresholds (≥219 and ≥2586 neutralization units/mL for toxins A and B, respectively).

Results: In participants previously given three 200-µg doses and placebo in the extension, toxin A and B neutralizing antibodies were above prevaccination levels 48 months post-dose 3 (36 months after placebo); 24.0% and 26.0% had toxin A and B antibodies at or above prespecified thresholds, respectively. Neutralizing antibodies increased post-dose 4 (12 months post-dose 3) and persisted to 36 months post-dose 4. Thirty days post-dose 4, all participants had toxin A and 86.5% to 100% had toxin B titers at or above prespecified thresholds. Local reactions were more frequent in vaccine recipients. Systemic and adverse event frequencies were similar across groups.

Conclusions: C difficile vaccine immune responses persisted 48 months post-dose 3. Dose 4 was immunogenic and well tolerated, supporting continued development. Clinical Trials Registration. ClinicalTrials.gov NCT02561195.

Keywords: Clostridioides difficile infection; United States; adults; nosocomial diarrhea; toxoid vaccine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . S. R., N. K., P. L., M. W. P., L. B., A. S. A., W. C. G., K. U. J., S. P. L., and C. W. are current or former employees of Pfizer Inc and may hold stock and/or stock options. J. P. received support from Pfizer as a study investigator. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
CONSORT diagram with participant dispositions in the (A) month and (B) day regimens during the extension phase. C difficile, Clostridioides difficile.
Figure 2.
Figure 2.
GMCs of toxin A– and toxin B–specific neutralizing antibodies in the initial and extension phases for the 200- and 100-μg dose levels. A, Month regimen. B, Day regimen. Arrows indicate days on which doses were administered. Error bars indicate 95% CIs. Blood samples were drawn on day 1 of the extension phase immediately before administration of dose 4. C difficile, Clostridioides difficile; GMC, geometric mean concentration (neutralizing units per milliliter).
Figure 3.
Figure 3.
Percentages of participants achieving prespecified levels of toxin A– and toxin B–specific neutralizing antibodies in the (A) month and (B) day regimens during the extension phase. Blood samples were drawn on day 1 of the extension phase immediately before administration of dose 4. Toxin A– and toxin B–specific thresholds were ≥219 and ≥2586 neutralization units/mL, respectively. Error bars indicate 95% CIs. C difficile, Clostridioides difficile.
Figure 4.
Figure 4.
Local reactions and systemic events by dose in the (A) month and (B) day regimens during the extension phase. 100P, 100 μg/placebo; 100, 100-μg Clostridioides difficile vaccine; 200P, 200 μg/placebo; 200, 200-μg Clostridioides difficile vaccine.
See this image and copyright information in PMC

References

    1. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372:1539–48. - PubMed
    1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257–62. - PubMed
    1. Bauer MP, Notermans DW, van Benthem BH, et al. . Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63–73. - PubMed
    1. Lessa FC, Mu Y, Bamberg WM, et al. . Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825–34. - PMC - PubMed
    1. Guh AY, Mu Y, Winston LG, et al. . Trends in US burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382:1320–30. - PMC - PubMed

Publication types

Associated data

Grants and funding